Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
2.26
Nov 06 • 3:59 PM ET Dollar change-0.17 Percentage change(-7.20%)
Aftermarket Close
2.29
Aftermarket • 7:59 PM ET Dollar change+0.03 Percentage change(1.55%)
Nov 06, 1:37 AMPacBio posts Q3 revenue $40.6 million (+6% YoY) and narrows 2026 revenue guidance to $155–$160 million
Index
RUT
Market Cap
705.65M
Enterprise Value
1.21B
Income
-131.23M
Sales
161.39M
Book/sh
-0.20
Cash/sh
0.64
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
485
IPO
Oct 27, 2010
P/E
-
Forward P/E
-
PEG
-
P/S
4.37
P/B
-
P/C
3.54
P/FCF
-
EV/EBITDA
-
EV/Sales
7.51
Quick Ratio
3.72
Current Ratio
4.62
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-0.43
EPS next Y
-0.45
EPS next Q
-0.13
EPS this Y
74.96%
EPS next Y
1.72%
EPS next 5Y
41.86%
EPS past 3/5Y
-9.18% -
Sales past 3/5Y
7.64% 15.19%
EPS Y/Y TTM
74.75%
Sales Y/Y TTM
4.41%
EPS Q/Q
3.72%
Sales Q/Q
5.52%
Insider Own
8.56%
Insider Trans
-2.51%
Inst Own
66.46%
Inst Trans
1.06%
ROA
-17.22%
ROE
-929.32%
ROIC
-20.44%
Gross Margin
32.52%
Oper. Margin
-98.09%
Profit Margin
-81.31%
SMA20
0.23%
SMA50
17.11%
SMA200
40.05%
Trades
Shs Outstand
312.24M
Shs Float
286.13M
52W High
3.43 -34.35%
52W Low
1.07 110.75%
Volatility
13.62% 12.35%
ATR (14)
0.29
RSI (14)
50.35
Beta
2.20
Rel Volume
0.77
Avg Volume
12.38M
Volume
9,564,157
Perf Week
-13.44%
Perf Month
-1.96%
Perf Quarter
96.09%
Perf Half Y
59.93%
Perf YTD
20.59%
Perf Year
26.69%
Perf 3Y
-66.84%
Perf 5Y
-92.27%
Perf 10Y
-67.27%
Prev Close
2.43
Price
2.26
Change %
-7.20%
Consensus
Buy
Avg. Price Target
$2.79
Implied Upside
+23.7%
Analysts12incl. previous ratings
Rating Distribution6 Buy · 5 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 09, 2026Resumed
UBS logoUUBS
Neutral$1.35-40.1%
Mar 06, 2026Downgrade
BCS logoBBarclays
Equal Weight → Underweight$1.50-33.5%
Nov 11, 2024Downgrade
UBS logoUUBS
Buy → Neutral
Jun 03, 2024Resumed
JEF logoJJefferies
Buy$4+77.4%
Apr 22, 2024Downgrade
JPM logoJJP Morgan
Overweight → Neutral
Apr 18, 2024Downgrade
GS logoGGoldman
Buy → Neutral$7 → $2.50+10.9%
Dec 14, 2023Initiated
SStephens
Overweight$11+387.8%
Dec 14, 2023Initiated
GGuggenheim
Neutral
Dec 13, 2023Initiated
WWolfe Research
Peer Perform
Nov 17, 2023Upgrade
UBS logoUUBS
Neutral → Buy$13 → $10+343.5%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gibson James R IISee RemarksOct 06 '26Option Exercise1.18500,000590,0001,745,663Oct 08 04:07 PM
Gibson James R IISee RemarksOct 06 '26Sale3.11661,8152,056,9211,083,848Oct 08 04:07 PM
Jim GibsonOfficerOct 06 '26Proposed Sale2.87661,8151,899,409Oct 06 04:23 PM
Van Oene MarkSee RemarksAug 17 '26Sale1.1326,91130,4092,705,853Aug 18 08:17 PM
MARK VAN OENEOfficerAug 17 '26Proposed Sale1.1326,91130,512Aug 17 04:08 PM
Gibson James R IISee RemarksApr 01 '26Sale1.3788,185120,8131,245,663Apr 03 04:05 PM
JAMES GIBSONOfficerApr 01 '26Proposed Sale1.3788,185120,778Apr 01 05:17 PM
HENRY CHRISTIAN OSee RemarksMar 03 '26Sale1.5112,49718,9203,581,813Mar 04 05:55 PM
Van Oene MarkSee RemarksMar 03 '26Sale1.516,5049,8472,243,634Mar 04 05:54 PM
Farmer MicheleSee RemarksMar 03 '26Sale1.512,9794,510305,948Mar 04 05:54 PM
MARK D. VAN OENEOfficerMar 03 '26Proposed Sale1.516,5049,849Mar 03 04:24 PM
CHRISTIAN HENRYOfficerMar 03 '26Proposed Sale1.5112,49718,924Mar 03 04:20 PM
Van Oene MarkSee RemarksFeb 17 '26Sale1.58129,790204,5491,797,745Feb 19 08:33 PM
Van Oene MarkSee RemarksFeb 18 '26Sale1.6355,10789,7691,742,638Feb 19 08:33 PM
HENRY CHRISTIAN OSee RemarksFeb 17 '26Sale1.58331,793522,9062,814,374Feb 19 08:31 PM
HENRY CHRISTIAN OSee RemarksFeb 18 '26Sale1.63140,874229,4842,673,500Feb 19 08:31 PM
Farmer MicheleSee RemarksFeb 17 '26Sale1.5835,21555,499234,044Feb 19 08:28 PM
Farmer MicheleSee RemarksFeb 18 '26Sale1.6314,95224,357219,092Feb 19 08:28 PM
MARK VAN OENEOfficerFeb 17 '26Proposed Sale1.58303,739478,693Feb 17 06:27 PM
CHRISTIAN HENRYOfficerFeb 17 '26Proposed Sale1.58606,312955,548Feb 17 06:25 PM
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Co-FounderDr. Stephen Turner Ph.D.